Prodeon Medical Receives FDA 510(k) Clearance for the Urocross® Expander System, a Novel Non-Permanent Retrievable Implant for Treating Urinary Symptoms Associated with Benign Prostatic Hyperplasia

Prodeon Medical Receives FDA 510(k) Clearance for the Urocross® Expander System, a Novel Non-Permanent Retrievable Implant for Treating Urinary Symptoms Associated with Benign Prostatic Hyperplasia

The Urocross® Expander System is designed to remodel the obstructing prostatic lobes during the six-month indwell time and is intentionally retrieved, leaving no permanent foreign material behind. SUNNYVALE, Calif., March 16, 2026 (GLOBE NEWSWIRE) — Prodeon M…

BPH management is not a singular intervention; it is a journey with longitudinal commitment to the patients evolving quality of life, said Dr. Daniel B. Rukstalis, Chair of Urology at St. Catherine H… [+2807 chars]
Prodeon Medical Receives FDA 510(k) Clearance for the Urocross® Expander System, a Novel Non-Permanent Retrievable Implant for Treating Urinary Symptoms Associated with Benign Prostatic Hyperplasia - FHMnews